20240405 Isofol_Notice_to_attend_ AGM_May 8 2024_ISO-419_final_2
Kurs
-0,41%
Likviditet
0,09 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-05-19 | N/A | Årsstämma |
| 2026-05-19 | 08:00 | Kvartalsrapport 2026-Q1 |
| 2026-02-18 | 08:00 | Bokslutskommuniké 2025 |
| 2025-11-12 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-08-26 | - | Kvartalsrapport 2025-Q2 |
| 2025-05-22 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2025-05-21 | - | Årsstämma |
| 2025-05-21 | - | Kvartalsrapport 2025-Q1 |
| 2025-02-19 | - | Bokslutskommuniké 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-10 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2024-05-08 | - | Årsstämma |
| 2024-05-08 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-20 | - | Bokslutskommuniké 2023 |
| 2024-01-04 | - | Extra Bolagsstämma 2023 |
| 2023-11-10 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-22 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-04 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2023-05-03 | - | Årsstämma |
| 2023-05-03 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | Bokslutskommuniké 2022 |
| 2023-02-13 | - | Extra Bolagsstämma 2022 |
| 2022-11-11 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-23 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-20 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2022-05-19 | - | Årsstämma |
| 2022-05-12 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-25 | - | Bokslutskommuniké 2021 |
| 2021-11-15 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-24 | - | Kvartalsrapport 2021-Q2 |
| 2021-06-23 | - | Årsstämma |
| 2021-05-21 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2021-05-20 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-14 | - | Extra Bolagsstämma 2021 |
| 2021-02-26 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-25 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2020-06-24 | - | Årsstämma |
| 2020-05-14 | - | Kvartalsrapport 2020-Q1 |
| 2020-05-05 | - | Extra Bolagsstämma 2020 |
| 2020-02-19 | - | Bokslutskommuniké 2019 |
| 2019-11-13 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-22 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-24 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2019-05-23 | - | Årsstämma |
| 2019-05-23 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-26 | - | Bokslutskommuniké 2018 |
| 2018-12-17 | - | Extra Bolagsstämma 2018 |
| 2018-11-14 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-21 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | Kvartalsrapport 2018-Q1 |
| 2018-05-04 | - | X-dag ordinarie utdelning ISOFOL 0.00 SEK |
| 2018-05-03 | - | Årsstämma |
| 2018-02-20 | - | Bokslutskommuniké 2017 |
| 2017-11-20 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-21 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-16 | - | Årsstämma |
| 2017-05-16 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
GOTHENBURG, Sweden, April 5, 2024 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), hereby invites the shareholders of Isofol Medical AB (publ), Reg. No. 556759-8064 based in Gothenburg, to the Annual General Meeting on Wednesday, May 8, 2024.
The information in the press release is intended for investors.
The shareholders in Isofol Medical AB (publ), Reg. No. 556759-8064, with its registered office in Gothenburg, are hereby invited to attend the annual general meeting held on Wednesday, May 8, 2024 at 2 p.m. at Biotech Center, Arvid Wallgrens backe 20, Fl. 5, Gothenburg, Sweden. Registration at the annual general meeting starts at 1:30 p.m. and ends when the meeting convenes.
The complete notice to attend is available in Swedish on the company´s website, www.isofolmedical.com
For further information, please contact
Isofol Medical AB (publ)
Magnus Hurst, CFO
E-mail: magnus.hurst@isofolmedical.com
Telephone: +46 (0)738 73 34 18
The information was submitted for publication, through the agency of the contact person set out above, at 11:00 CEST on April 5, 2024.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.